It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Inflammation is a physiological process whose deregulation causes some diseases including cancer. Nuclear Factor kB (NF-kB) is a family of ubiquitous and inducible transcription factors, in which the p65/p50 heterodimer is the most abundant complex, that play critical roles mainly in inflammation. Glucocorticoid Receptor (GR) is a ligand-activated transcription factor and acts as an anti-inflammatory agent and immunosuppressant. Thus, NF-kB and GR are physiological antagonists in the inflammation process. Here we show that in mice and humans there is a spliced variant of p65, named p65 iso5, which binds the corticosteroid hormone dexamethasone amplifying the effect of the glucocorticoid receptor and is expressed in the liver of patients with hepatic cirrhosis and hepatocellular carcinoma (HCC). Furthermore, we have quantified the gene expression level of p65 and p65 iso5 in the PBMC of patients affected by SARS-CoV-2 disease. The results showed that in these patients the p65 and p65 iso5 mRNA levels are higher than in healthy subjects. The ability of p65 iso5 to bind dexamethasone and the regulation of the glucocorticoid (GC) response in the opposite way of the wild type improves our knowledge and understanding of the anti-inflammatory response and identifies it as a new therapeutic target to control inflammation and related diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Istituto per la Ricerca e l’Innovazione Biomedica del Consiglio Nazionale delle Ricerche, Palermo, Italy; Università degli Studi di Palermo, Dipartimento Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517)
2 Istituto per la Ricerca e l’Innovazione Biomedica del Consiglio Nazionale delle Ricerche, Palermo, Italy (GRID:grid.10776.37)
3 Università di Bologna, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)
4 Università degli Studi di Palermo, Dipartimento Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517)
5 Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione, Dipartimento di Ricerca, IRCCS-ISMETT, Palermo, Italy (GRID:grid.419663.f) (ISNI:0000 0001 2110 1693)
6 Azienda Ospedaliera di Rilevanza Nazionale e Alta Specializzazione ARNAS Civico, Unità COVID, Dipartimento di Medicina Interna, Palermo, Italy (GRID:grid.419995.9); Università degli Studi di Palermo, Dipartimento PROMISE, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517)
7 Rilevanza Nazionale e Alta Specializzazione Ospedaliera Trust ARNAS Civico, Laboratorio Specialistico di Oncologia, Palermo, Italy (GRID:grid.419995.9)
8 Rilevanza Nazionale e Alta Specializzazione ARNAS Civico, Unità Organizzativa Complessa di Patologia Clinica, Palermo, Italy (GRID:grid.419995.9)